• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺鳞状细胞癌中 mA 修饰的肿瘤微环境特征及预后作用

Tumor microenvironment characteristics and prognostic role of mA modification in lung squamous cell carcinoma.

作者信息

Li Pei, Xiong Peiyu, Li Xinyun, Zhang Xiaobo, Chen Xu, Zhang Wei, Jia Bo, Lai Yu

机构信息

School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.

Sichuan College of Traditional Chinese Medicine, Mianyang, 621000, China.

出版信息

Heliyon. 2024 Feb 28;10(5):e26851. doi: 10.1016/j.heliyon.2024.e26851. eCollection 2024 Mar 15.

DOI:10.1016/j.heliyon.2024.e26851
PMID:38455573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10918158/
Abstract

BACKGROUND

It has recently been determined that N6-methyladenosine (mA) RNA methylation regulators have prominent effects on several cancers. However, the potential role of mA modification in lung squamous cell carcinoma (LUSC) remains unclear.

METHODS

We evaluated the modification pattern of mA and studied the biological function of mA regulators in LUSC. Then, we constructed the m6Ascore to predict the prognosis of LUSC and analyzed the relationship between the m6Ascore and tumor mutation burden, immune cell infiltration, and immunotherapy.

RESULT

In the unsupervised consensus cluster analysis, three different m6Aclusters were identified, which correspond to an immune activation state, a moderate immune activation state, and an immune tolerance state. Forty-two genes related to the mA phenotype were used to construct the m6Ascore; subsequently, multiple validations of the m6Ascore were carried out to determine the relationship between the score and immune cell infiltration and response to CTLA-4/PD-1 inhibitor treatment. Further analysis revealed that the m6Ascore could effectively predict the prognosis of LUSC and that the mA phenotype-related genes, and , might be potential biomarkers.

CONCLUSION

These findings highlight the potential role of mA modification in the prognosis, TME, and immunotherapy of LUSC and have profound implications for developing more effective personalized treatment strategies for LUSC.

摘要

背景

最近已确定N6-甲基腺苷(mA)RNA甲基化调节剂对多种癌症有显著影响。然而,mA修饰在肺鳞状细胞癌(LUSC)中的潜在作用仍不清楚。

方法

我们评估了mA的修饰模式,并研究了mA调节剂在LUSC中的生物学功能。然后,我们构建了m6A评分来预测LUSC的预后,并分析了m6A评分与肿瘤突变负荷、免疫细胞浸润和免疫治疗之间的关系。

结果

在无监督一致性聚类分析中,识别出三种不同的m6A簇,分别对应免疫激活状态、中度免疫激活状态和免疫耐受状态。使用42个与mA表型相关的基因构建m6A评分;随后,对m6A评分进行了多次验证,以确定该评分与免疫细胞浸润以及对CTLA-4/PD-1抑制剂治疗反应之间的关系。进一步分析表明,m6A评分可以有效预测LUSC的预后,并且与mA表型相关的基因 和 可能是潜在的生物标志物。

结论

这些发现突出了mA修饰在LUSC的预后、肿瘤微环境和免疫治疗中的潜在作用,对开发更有效的LUSC个性化治疗策略具有深远意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/6d26bc199de4/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/58274e0b6817/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/275924ad2a65/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/b65d59a9dc41/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/8e4192735b2f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/7b61df37b43c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/d5e88a7c7b57/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/6d26bc199de4/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/58274e0b6817/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/275924ad2a65/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/b65d59a9dc41/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/8e4192735b2f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/7b61df37b43c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/d5e88a7c7b57/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72de/10918158/6d26bc199de4/gr7.jpg

相似文献

1
Tumor microenvironment characteristics and prognostic role of mA modification in lung squamous cell carcinoma.肺鳞状细胞癌中 mA 修饰的肿瘤微环境特征及预后作用
Heliyon. 2024 Feb 28;10(5):e26851. doi: 10.1016/j.heliyon.2024.e26851. eCollection 2024 Mar 15.
2
Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.非小细胞肺癌中 m6A RNA 甲基化调控因子与肿瘤免疫微环境的综合分析
Dis Markers. 2022 Feb 9;2022:2989200. doi: 10.1155/2022/2989200. eCollection 2022.
3
mA regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer.mA 调节剂介导的甲基化修饰模式及胃癌肿瘤微环境浸润特征。
Mol Cancer. 2020 Mar 12;19(1):53. doi: 10.1186/s12943-020-01170-0.
4
Identification of prognostic m6A modification patterns and score system in melanoma patients.鉴定黑色素瘤患者预后的 m6A 修饰模式和评分系统。
Medicine (Baltimore). 2024 Apr 26;103(17):e37950. doi: 10.1097/MD.0000000000037950.
5
Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.胰腺腺癌中N6-甲基腺嘌呤修饰模式与肿瘤免疫微环境分析
Front Genet. 2022 Jan 3;12:752025. doi: 10.3389/fgene.2021.752025. eCollection 2021.
6
Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.m6A RNA甲基化调节剂模式的定量分析是一种潜在的预后生物标志物,且与胰腺腺癌的肿瘤免疫微环境相关。
BMC Cancer. 2021 Jul 31;21(1):876. doi: 10.1186/s12885-021-08550-9.
7
N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.N6-甲基腺嘌呤甲基化修饰模式揭示胰腺腺癌中的免疫特征。
Cancer Cell Int. 2022 May 23;22(1):199. doi: 10.1186/s12935-022-02614-x.
8
m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.m6A 调节子介导的甲基化修饰模式及肝癌肿瘤微环境浸润特征
Aging (Albany NY). 2021 Aug 30;13(16):20698-20715. doi: 10.18632/aging.203456.
9
Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.与膀胱癌多组学特征相关的N6-甲基腺苷修饰模式的综合分析
Front Med (Lausanne). 2021 Dec 23;8:757432. doi: 10.3389/fmed.2021.757432. eCollection 2021.
10
m6A-Mediated Tumor Invasion and Methylation Modification in Breast Cancer Microenvironment.m6A介导的乳腺癌微环境中的肿瘤侵袭与甲基化修饰
J Oncol. 2021 Oct 27;2021:9987376. doi: 10.1155/2021/9987376. eCollection 2021.

引用本文的文献

1
A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma.一种新型的与缺氧和乳酸代谢相关的预后标志物,用于描绘骨肉瘤的免疫图谱并预测免疫治疗反应。
Front Immunol. 2024 Nov 6;15:1467052. doi: 10.3389/fimmu.2024.1467052. eCollection 2024.
2
RNA modifications in cancer immune therapy: regulators of immune cells and immune checkpoints.癌症免疫治疗中的 RNA 修饰:免疫细胞和免疫检查点的调节剂。
Front Immunol. 2024 Sep 20;15:1463847. doi: 10.3389/fimmu.2024.1463847. eCollection 2024.

本文引用的文献

1
The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma.基于m6A长链非编码RNA的肺鳞状细胞癌总生存预后模型的构建与验证
J Thorac Dis. 2022 Oct;14(10):4055-4072. doi: 10.21037/jtd-22-1185.
2
N6-Methyladenosine (mA)-Related lncRNAs Are Potential Signatures for Predicting Prognosis and Immune Response in Lung Squamous Cell Carcinoma.N6-甲基腺苷(m⁶A)相关长链非编码RNA是预测肺鳞状细胞癌预后和免疫反应的潜在标志物。
J Oncol. 2022 Sep 2;2022:5240611. doi: 10.1155/2022/5240611. eCollection 2022.
3
-Methyladenosine-Related Long Non-Coding RNAs Are Identified as a Potential Prognostic Biomarker for Lung Squamous Cell Carcinoma and Validated by Real-Time PCR.
N6-甲基腺苷相关长链非编码RNA被鉴定为肺鳞状细胞癌潜在的预后生物标志物并通过实时聚合酶链反应验证。
Front Genet. 2022 Jun 3;13:839957. doi: 10.3389/fgene.2022.839957. eCollection 2022.
4
Identification of a N6-Methyladenosine (m6A)-Related lncRNA Signature for Predicting the Prognosis and Immune Landscape of Lung Squamous Cell Carcinoma.用于预测肺鳞状细胞癌预后和免疫格局的N6-甲基腺苷(m6A)相关长链非编码RNA特征的鉴定
Front Oncol. 2021 Nov 18;11:763027. doi: 10.3389/fonc.2021.763027. eCollection 2021.
5
Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.基于 m6A RNA 甲基化修饰和免疫微环境的肺腺癌分子亚型特征。
BMC Cancer. 2021 Aug 20;21(1):938. doi: 10.1186/s12885-021-08655-1.
6
N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.N6-甲基腺苷(m6A)RNA 甲基化调节剂 SNRPC 是一种预后生物标志物,与肝癌的免疫治疗相关。
World J Surg Oncol. 2021 Aug 13;19(1):241. doi: 10.1186/s12957-021-02354-8.
7
Integrated analysis of mA mRNA methylation in rats with monocrotaline-induced pulmonary arterial hypertension.马钱子碱诱导肺动脉高压大鼠 mA mRNA 甲基化的综合分析。
Aging (Albany NY). 2021 Jul 26;13(14):18238-18256. doi: 10.18632/aging.203230.
8
Comprehensive Analysis of the Prognostic Role and Mutational Characteristics of m6A-Related Genes in Lung Squamous Cell Carcinoma.肺鳞状细胞癌中m6A相关基因的预后作用及突变特征的综合分析
Front Cell Dev Biol. 2021 Mar 25;9:661792. doi: 10.3389/fcell.2021.661792. eCollection 2021.
9
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.免疫检查点阻断在转移性肺鳞癌中的现状。
Molecules. 2021 Mar 5;26(5):1392. doi: 10.3390/molecules26051392.
10
N6-methyladenosine modification of HCV RNA genome regulates cap-independent IRES-mediated translation via YTHDC2 recognition.N6-甲基腺苷修饰 HCV RNA 基因组通过 YTHDC2 识别调节帽非依赖性 IRES 介导的翻译。
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10). doi: 10.1073/pnas.2022024118.